Engaging Thought Leadership
Over 45 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
Gene Therapy Development 2024
13 - 14 June 2024 | London, UK
Join leaders at the forefront of gene therapy development, offering insights on navigating the latest advancements and challenges in gene therapy production.
Gene Therapy Development 2024
Meet Our Expert Speakers
Gene Therapy Development 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Below are some of our featured speakers:
Alba Guijarro Belmar
Head of Vector Development,
Sania Therapeutics
Avencia Sanchez-Mejias
CEO and Co-Founder,
Integra Therapeutics
Charlotte Smerdon
Senior Director, Clinical Operations,
Purespring Therapeutics
Giandomenico Turchiano
Associate Director,
UCL/AstraZeneca
Nathalie Cartier-Lacave
Senior Vice President Neurobiology,
AskBio
All Speakers
Alberto del Rio Espinola
Director,
GentiBio Inc
Amin Hajitou
Professor, Reader in Neuroinflammation,
Imperial College London
Breech Conrad Odu
Process Development Scientist,
Merck Life Sciences
Claire Kerridge
Head of Gene Therapy,
MHRA
Claudio Mussolino
Group Leader,
Medical Center - University of Freiburg
Ekaterini (Nina) Kotsopoulou
CTO,
AAVantgerde
Elina Hessels
Associate Director Analytical Platforms,
uniQure
Ellina Allais
Regulatory Affairs Senior Director,
Cellectis S.A.
Eugenio Macchiarulo
Director MSAT,
Barinthus Bio
Isabelle Richard
Director of Research,
Genethon
James Norton
Director of Analytical Development,
MeiraGTx
Jane Kinghorn
Director Translational Research Office,
University College London
Johnson Varghese
VP, Head of Analytical Research and Development,
Beam Therapeutics
Julia Berretta
CEO,
Genespire
Khalid Saeed
Senior scientist,
AstraZeneca
Koval Smith
Senior Manager DS/DP MSAT,
Orchard Therapeutics
Laurence Guianvarc'h
Head of Upstream & Downstream Process Development,
Nantes University
Lilian Hook
Director Cell, Apheresis and Gene Therapies,
NHS Blood and Transplant
.jpg?length=600&name=d6849f03-22a9-47a5-aef2-a28b6e43a39a-2-11764368speaker_photo-Profil_Michel_2-(2).jpg)
Michel Degueldre
Lead GT Biophysical SCiences,
UCB
Nathalie Uzcategui
Senior Scientist,
Hansa BioPharma
Otmane Boussif
Chief Technology Officer,
Anjarium Biosciences
Pamela Whalley
Associate Director CMC,
Complementtx
Patricia Lareo
Value Chain Capability Lead Gene Therapy,
Roche
Paul Carter
Senior Director MSAT,
Quell Therapeutics
Peter Pechan
Head of Vector Biology and Discovery,
UCB Biosciences
Rodolphe Clerval
CEO,
Coave Tx
Senior Representative
,
AviadoBio
Simon Eaglestone
Director, Program Management,
Bloomsburygtx
Victor Dillard
VP, Strategy & Operations,
Resolution Therapeutics
Vinciane De Cupere
Technical Lead Gene Therapy,
UCB
Yu-Tsan (Richard) Liu
Sr. Scientist,
UCB Pharma
Meet Our Esteemed Sponsors
Silver Sponsors
Progen Biotechnik GmbH
Silver Sponsor
PROGEN was founded in 1983 by four scientists from Heidelberg, Germany, who joined forces to manufacture and supply high quality antibodies for biomedical research. We help scientists worldwide drive biopharmaceutical and diagnostic progress to provide high-quality and reliable treatments for patients. Our mission is to make new therapies safe and affordable and to improve existing research processes. The PROGEN team consists of bioscientists and adeno-associated virus (AAV) experts who collaborate with specialists around the world. Our products are essentials for research in science and industry. We are more than just a manufacturer of antibodies, AAV gene therapy tools, density gradient media, and phage display technologies: We strive to understand the needs of scientists to develop solutions to jointly address challenges in academic research, biotechnology and pharma.
Sartorius BIA Separations
Silver Sponsor
Sartorius BIA Separations develops and manufactures market-leading CIM® monolithic chromatographic columns for the purification and analysis of large biomolecules, such as viruses, plasmids, and mRNA, which are applied in cell and gene therapies. The company’s Cornerstone® Biomanufacturing Development Services are the result of more than 25 years of hands-on experience with the most challenging biopharmaceutical products and offer a comprehensive approach of integrated process development solutions and novel technology designed to improve the robustness and yield of large biomolecules production while improving the safety of therapeutic products. Sartorius BIA's technology for manufacturing-scale purification is already used in the production of the first commercialized advanced therapeutics;the company also has a keen presence with novel drug candidates in the clinical pipeline.
Bronze Sponsors
Rentschler ATMP Limited
Bronze Sponsor
Rentschler Biopharma is a leading global CDMO, focused exclusively on client projects. Thanks to our 50 years of proven scientific expertise in biotechnology, we count ourselves among the leaders in the industry. From our headquarters in Laupheim, Germany, and our sites in Milford, USA, and Stevenage, UK, we offer end-to-end solutions including biopharmaceutical and cell and gene therapy (CGT) process development and cGMP manufacturing. Our Center of Excellence for CGTs is located in Stevenage, UK, the largest cell and gene therapy cluster in Europe. At Rentschler Biopharma's ATMP site, we are dedicated to advancing cell and gene therapy products from development to cGMP manufacturing of high quality viral vectors for our clients and their patients.
Network & Programme Sponsors
Advanced Instruments
Network & Programme Sponsor
Advanced Instruments is a global provider of scientific and analytical solutions for the biopharma and clinical industries Our company’s innovations have helped organizations improve quality, achieve reliable outcomes, and increase productivity for more than 65 years. Our focus on service, quality, and reliability has made us a leading developer and manufacturer of analytical instruments and services for the biopharmaceutical, clinical, and food & beverage industries. Our newest addition, the Artel portfolio, includes leading analytical instruments, software and services that validate, automate, and calibrate critical liquid handling processes and instrumentation. Our Solentim portfolio delivers best-in-class imaging and single-cell deposition technologies for cell line development workflows. And our OsmoTECH® and OsmoPRO® micro-osmometers support the workflows that labs worldwide rely on for the delivery of accurate and timely results.
NOF Europe
Network & Programme Sponsor
NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF's LNP platform composed of COATSOME® SS Series, novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF’s LNP platform is becoming adopted in clinical planning by NOF collaborators.
SGS Vitrology
Network & Programme Sponsor
With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products. SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.
Enhancing Gene Editing Efficiency: Multi-Tailed mRNA Integration in CRISPR-Cas9 Systems
A study conducted by the Broad Institute and the Massachusetts Institute of Technology (MIT) demonstrated that when multi-tailed mRNAs were integrated into a CRISPR-Cas9 system they proved to be more efficient gene editors than unmodified mRNA.
Post-Event Proceedings – Gene Therapy Development & Manufacturing 2023
Concise and insightful summaries of presentations delivered by prominent thought leaders at Gene Therapy Development & Manufacturing 2023.
Curing HIV with cell & gene therapy?
It is now possible to live a long and near normal life with HIV, but what is the likelihood of a permanent cure?
Proactive Approaches to Cell Culture Media and Process Control Strategies
Merck invests $25 million in a Kansas cell culture media plant, aiming to meet rising demand for advanced therapeutics while aligning with sustainability goals.
In Conversation With… Sophie Mountcastle, Network Manager, Innovation Hubs for Gene Therapies
Here, we discuss the crucial role of a collaborative network for gene therapy development across the UK and some of the successes seen to date.
How Current and New Technologies can Overcome Challenges in Adherent Scale-Up
ILEC Conference Centre
47 Lillie Rd
London
SW6 1UD
United Kingdom
By Underground
Sitting at the edge of zone 1, West Brompton and Earls Court stations are both within walking distance giving easy access to all central districts of London and Heathrow Airport. Transport for London tube map.
By Car
ILEC is a quarter of a mile (400m) from the A4, providing easy access to the M4, M5 and M40.
By Air
Heathrow (LHR): 21 km - Approximately 30 minutes in light traffic. You can also reach the airport directly by London Underground, on the Piccadilly line. Gatwick (LGW): 45 Km - Approximately an hour in light traffic. It is 40 minutes by train from West Brompton station via Clapham Junction. Direct shuttle available with Easy Bus. London City (LCY): 21 km - Approximately 45 minutes in light traffic.
Parking
There is a car park adjacent to ILEC with 140 parking bays. The parking is NOT managed by ILEC so spaces cannot be reserved and may become full during busy events. Guests and delegates can benefit from preferential parking rates as follows: Up to 2 hours £7 Up to 4 hours £11 Up to 6 hours £14 Up to 9 hours £16 (£21 for non-residents) Up to 12 hours £20 (£26 for non-residents) Up to 24 hours (overnight) £26
Oxford Global have secured a number of bedrooms at ibis London Earls Court at a reduced rate:
Wednesday 12th June 2024 – £176, breakfast included
Thursday 13th June 2024 – £176, breakfast included
Should you wish to book a room, please click here.
The final cut-off date to book bedrooms is Monday 27th May 2024 – any bookings after this date are subject to availability and rates. Please note, that any cancellations within 14 days prior to arrival are subject to cancellation charges.
Additionally, we kindly remind all attendees to only book their accommodation if they are registered for the event. This ensures that accommodations are available for those who have officially secured their attendance.
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Gene Therapy Development 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
